




RealRate

PHARMACEUTICAL 2020

Albireo Pharma INC
Rank 182 of 363



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Albireo Pharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Albireo Pharma INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 56% points. The greatest weakness of Albireo Pharma INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 71% points.

The company's Economic Capital Ratio, given in the ranking table, is 245%, being 7.2% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	141,799
Cost of Goods Sold	0
Intangible Assets	17,260
Liabilities, Current	18,924
Liabilities, Non-Current	4,270
Other Assets	5,413
Other Compr. Net Income	2,159
Other Expenses	2,210
Other Liabilities	48,714
Other Net Income	-1,605
Other Revenues	9,636
Property and Equipment	597
Research and Development	45,575
Selling, General and Administrative Expense	22,963

Output Variable	Value in 1000 USD
Assets	165,069
Liabilities	71,908
Expenses	70,748
Revenues	9,636
Stockholders Equity	93,161
Net Income	-62,717
Comprehensive Net Income	-61,638
BaseVar	160,562
ECR before LimitedLiability	119%
Economic Capital Ratio	245%